Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing.

Celgene International Sàrl (NASDAQ: CELG) reported two REVLIMID (lenalidomide) Phase II studies, presented today at the 50th American Society of Hematology Meeting, both demonstrated high response rates and manageable side effects in patients previously untreated with symptomatic chronic lymphocytic leukemia (CLL).

In 1958, Ohio State University cancer researcher Dr. Bertha Bouroncle first identified a deadly disease now known as hairy-cell leukemia, a once fatal disease that can now be effectively treated.

New study finds the majority of acute lymphoblastic leukemia relapse cases arise from a cell already present at the time of diagnosis

Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL).

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

Blocking the signals from a protein that activates cells in the immune system could help kill cells that cause a rare form of blood cancer, according to physicists and oncologists who combined computer modeling and molecular biology in their discovery.

A recently identified cancer-causing protein makes the anti-leukemia drug imatinib, less effective. By blocking the protein, an international team of researchers was able to slow the spread of leukemia cells in culture.

A new twist on a well-known cell sorting technique may allow physicians to diagnose rare leukemias in hours instead of weeks, according to a study by researchers at the Stanford University School of Medicine and UC-San Francisco.

Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.

Nearly a third of leukemia patients do not respond to chemotherapy, but this is not usually discovered until they have already endured a week-long chemotherapy treatment and waited a month to see whether it has worked. A new study shows that PET scans could tell how well a patient is responding after just one day of chemotherapy.

Angiocidin, a tumor-inhibiting novel protein discovered by Temple University researchers, may also have a role as a new therapeutic application in treating leukemia, according to a study by the researchers.